ArticleJournal of experimental & clinical cancer research : CR2022

CBL0137 impairs homologous recombination repair and sensitizes high-grade serous ovarian carcinoma to PARP inhibitors.

Xue Lu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.